Database	Time span	Search strategy
The Cochrane Hepato‐Biliary Controlled Trials Register	4 May 2022	(rifaximin* OR xifaxan* OR rcifax* OR rifagut*) AND (encephalopath* OR liver disease* OR cirrho*)
Cochrane Central Register of Controlled Trials	Latest issue (2022, Issue 5)	#1 rifaximin* or xifaxan* or rifagut* or Rcifax* #2 MeSH descriptor: [Hepatic Encephalopathy] explode all trees #3 MeSH descriptor: [Liver Diseases] explode all trees #4 MeSH descriptor: [Fibrosis] explode all trees #5 encephalopath* or liver disease* or cirrho* #6 #2 or #3 or #4 or #5 #7 #1 and #6
MEDLINE Ovid	1946 to 4 May 2022	1. (rifaximin* or xifaxan* or rifagut* or Rcifax*).mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub‐heading word, keyword heading word, organism supplementary concept word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonym 2. exp Hepatic Encephalopathy/ 3. exp Liver Diseases/ 4. exp Fibrosis/ 5. (encephalopath* or liver disease* or cirrho*).mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub‐heading word, keyword heading word, organism supplementary concept word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms] 6. 2 or 3 or 4 or 5 7. 1 and 6 8. (randomized controlled trial or controlled clinical trial).pt. or clinical trials as topic.sh. or trial.ti. 9. (random* or blind* or placebo* or meta‐analys*).mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub‐heading word, keyword heading word, organism supplementary concept word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms] 10. 7 and (8 or 9)
Embase Ovid	1974 to 4 May 2022	1. exp rifaximin/ 2. (rifaximin* or xifaxan* or rifagut* or Rcifax*).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word] 3. 1 or 2 4. exp hepatic encephalopathy/ 5. exp liver disease/ 6. exp fibrosis/ 7. (encephalopath* or liver disease* or cirrho*).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word] 8. 4 or 5 or 6 or 7 9. 3 and 8 10. Randomized controlled trial/ or Controlled clinical study/ or trial.ti. 11. (random* or blind* or placebo* or meta‐analys*).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word] 12. 9 and (10 or 11)
LILACS (Bireme)	1982 to 4 May 2022	(rifaximin$ or xifaxan$ or rifagut$ or Rcifax$) [Words] and (encephalopath$ or liver disease$ or cirrho$) [Words]
Science Citation Index Expanded	1900 to 4 May 2022	#5 #4 AND #3 #4 TI=(random* or blind* or placebo* or meta‐analys* or trial*) OR TS=(random* or blind* or placebo* or meta‐analys*) #3 #2 AND #1 #2 TS=(encephalopath* or liver disease* or cirrho*) #1 TS=(rifaximin* or xifaxan* or rifagut* or Rcifax*)
Conference Proceedings Citation Index – Science (Web of Science)	1990 to 4 May 2022	#5 #4 AND #3 #4 TI=(random* or blind* or placebo* or meta‐analys* or trial*) OR TS=(random* or blind* or placebo* or meta‐analys*) #3 #2 AND #1 #2 TS=(encephalopath* or liver disease* or cirrho*) #1 TS=(rifaximin* or xifaxan* or rifagut* or Rcifax*)